Andras Rosta
Overview
Explore the profile of Andras Rosta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herold M, Hoster E, Janssens A, McCarthy H, Tedeschi A, Pocock C, et al.
Hemasphere
. 2022 Mar;
6(3):e699.
PMID: 35233508
The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL)...
2.
Ditroi T, Nagy A, Martinelli D, Rosta A, Kozich V, Nagy P
Free Radic Biol Med
. 2019 Apr;
136:146-158.
PMID: 30970274
A rapidly increasing number of studies report on widespread biological functions for endogenous hydrogen sulfide. However, the use of multiple, chemically distinct analytical methods to measure free hydrogen sulfide levels...
3.
Trotman J, Barrington S, Belada D, Meignan M, MacEwan R, Owen C, et al.
Lancet Oncol
. 2018 Oct;
19(11):1530-1542.
PMID: 30309758
Background: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim...
4.
Connors J, Jurczak W, Straus D, Ansell S, Kim W, Gallamini A, et al.
N Engl J Med
. 2017 Dec;
378(4):331-344.
PMID: 29224502
Background: Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods: We conducted an open-label, multicenter, randomized phase 3 trial involving patients...
5.
Schneider T, Rosta A, Losonczy H, Radvanyi G, Ujj G, Egyed M, et al.
Pathol Oncol Res
. 2017 Apr;
24(2):199-205.
PMID: 28432650
Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to...
6.
Bartal A, Matrai Z, Szucs A, Belinszkaja G, Langmar Z, Rosta A
Orv Hetil
. 2012 Jan;
153(2):66-78.
PMID: 22217686
Each aspect of oncological care is widely affected by the spread of oral anticancer agents, which raises several questions in terms of safe medication use and patient adherence. Over the...
7.
Rosta A
Orv Hetil
. 2011 Jun;
152(29):1144-55.
PMID: 21712179
Type 2 diabetes mellitus and malignant tumors are frequent diseases worldwide. The incidence of these two diseases is growing continuously and causes serious health care problem. Population based epidemiologic studies...
8.
Bartal A, Matrai Z, Rosta A, Szucs A
Magy Onkol
. 2011 May;
55(1):14-20.
PMID: 21617787
Extravasation of cytostatics occurs when an infusion containing a cytotoxic drug leaks into the surrounding perivascular and subcutaneous tissues. Incidence of cytostatic extravasation is found to be 0.1-6% according to...
9.
Schneider T, Toth E, Lovey J, Molnar Z, Deak B, Varady E, et al.
Orv Hetil
. 2011 Apr;
152(19):735-42.
PMID: 21498163
Introduction: Primary mediastinal lymphoma (PMBCL) is an aggressive diffuse large B-cell lymphoma entity. It is a rare disease with specific clinical symptoms. The tumor is predominantly localized in the mediastinum...
10.
Muller J, Illes A, Molnar Z, Rosta A, Varoczy L, Kovacs G
J Pediatr Hematol Oncol
. 2011 Feb;
33(2):e60-3.
PMID: 21285900
Background: The aim of our work was to compare the treatment modalities and the survival rates in adolescents (14 to 21 y) with Hodgkin lymphoma (HL) treated with adult (A)...